CPSE:NOVO BPharmaceuticals
Novo Nordisk Puts Wegovy Pill Ahead Of Lilly Rival In Obesity Race
Novo Nordisk released cross trial comparison data on its oral Wegovy pill versus Eli Lilly's newly approved Foundayo pill.
The company reported that oral Wegovy achieved greater weight loss and showed better tolerability than Foundayo.
New patient preference data indicated a stronger preference for Wegovy's treatment profile over Lilly's oral option.
For investors tracking CPSE:NOVO B, this update comes with the shares around DKK236.9 and a mixed return profile, including a 23.5% gain over...